Parkinson's Vax Enters Clinical Trials

Researchers in Vienna are starting a Phase I trial on the first ever vaccine with a potential to treat the neurodegenerative disease.

By | June 7, 2012

Alpha-synuclein accretions (brown spots) accumulate in the brains of Parkinson's patientsWikimedia Commons, Jensflorian

Alpha-synuclein accretions (brown spots) accumulate in the brains of Parkinson's patients WIKIMEDIA COMMONS, JENSFLORIAN

A new vaccine that has the potential to treat Parkinson's disease is entering a Phase I clinical trial in Vienna. The first-of-its-kind vaccine, PD01A, aims to ramp up an immune response to the alpha-Synuclein (alpha-syn) protein, which is involved in the onset and progression of Parkinson's. Austrian biotech AFFiRiS is testing the vaccine with support from the Michael J. Fox Foundation.

"Worldwide, for the first time immunotherapy is applied for the treatment of Parkinson's," AFFiRiS CEO Walter Schmidt said in a statement. "PD01A is the first medication worldwide aiming for clinical efficacy by modulating the metabolic pathway of alpha-syn."

Hat tip to Medical News Today.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  3. Researchers Build a Cancer Immunotherapy Without Immune Cells
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech